STAT

APRIL 12, 2024

The new legislation would also allow another state entity, the Rare Disease Advisory Council, to review such drugs in hopes of giving more voice to patients. The original bill was introduced over concerns that patients may lose access to rare disease drugs if companies halt sales or decide not to invest in developing such medicines.

100

100

pharmaphorum

OCTOBER 3, 2022

‘Clearer’ data isn’t expected until 2024, with results from a late-stage phase 3 PHOENIX trial of around 600 patients due at that time. Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost. ALS affects over 30,000 people in the US.

Insurance 52

Insurance FDA 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels.

Communication 87

Communication Insurance Packaging Pharmaceutical Companies 87

pharmaphorum

JANUARY 31, 2023

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Additionally, when patients are prescribed medication, they are often unaware of the mechanism of action, potential side effects, interactions, and contraindications.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52

The FDA Law Blog

JUNE 27, 2023

James’s status as a 15-year champion for bringing patient voices to the table with FDA and industry decision-makers was also considered. James is recognized as helping fundamentally shift the culture to consider the patient voice as an integral part of drug development. Dormer Jeffrey N. Gibbs Paul M. Hyman Alan M.

FDA 81

FDA 81

pharmaphorum

MAY 24, 2021

Robb DeFilippis, managing director, life sciences, for end-to-end global creative production and sourcing partner Tag in the Americas agrees. It can be used for sales, marketing and patient communication materials, in print or digital form.

Communication 89

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 89

pharmaphorum

NOVEMBER 28, 2022

Owkin is committed to unlocking the vast potential held within patient data by developing technologies that overcome the privacy and security challenges that until now impacted research.”. Owkin in particular has bagged some high-profile, high-price tag development deals with the likes of Bristol-Myers Squibb and Sanofi.

Hospitals 72

Hospitals 72